News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RXi Pharmaceuticals (RXII) Plans to Split into Two Public Firms



9/26/2011 8:09:04 AM

RXi Pharmaceuticals Corp. /quotes/zigman/109669/quotes/nls/rxii RXII -12.84% said it plans to split into two publicly traded companies later this year, separating its oncology and gene therapy businesses. The biotechnology company will change its name to Galena Biopharma but will continue to trade under the ticker symbol RXII until the completion of the spinoff of RXi Pharmaceuticals. After the split, Galena will focus on cancer therapies, while RXi will develop therapies that use RNA interference, which help stem the expression of a specific gene that may be overexpressed in a disease.

Read at Market Watch
Read at Street Insider


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES